Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2023 Net Income-$4.17M-$4.17MN/M vs Q2 2023 EPS Diluted-$2.47-$2.47N/M vs Q2 2023 Operating Income-$2,908,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,603,000N/M ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end